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large populations of patients and controls, regardless of ABCB4 status.
Our secondary aim was to estimate the frequency of the syndrome
among patients with symptomatic cholelithiasis.
Method: This retrospective case-control study included all patients
diagnosed with LPAC syndrome based on original criteria in 4 French
centers (one referral center and 3 general hospitals). Patients who
underwent cholecystectomy for classical gallstone disease in a
general hospital served as controls. A multivariate logistic regression
model adjusted on age, sex, body mass index, and metabolic
syndrome was used to identify the variables independently asso-
ciated with LPAC syndrome. A diagnostic score was developed and
validated. Patients were compared according to ABCB4 mutation
status. Frequency of LPAC syndrome was estimated based on the
number of all patients cholecystectomized for gallstones during the
same period.
Results: 512 adult patients (306 cases, 206 controls) were included.
In addition to the 3 previously established criteria (age at first
symptoms <40; recurrence of symptoms after cholecystectomy;
ultrasound signs of intrahepatic microlithiasis), 2 new criteria were
identified: (1) features suggestive of common bile duct lithiasis, (2)
lack of cholecystitis evidence. The new score had a high diagnostic
performance (c-statistic: 0.99). ABCB4 mutation was present in 43%
of LPAC patients. These patients had an increased risk of intrahepatic
cholestasis of pregnancy (ICP; 34% vs. 17%), chronic elevation of GGT
(33% vs. 14%) and transaminases (16% vs. 8%), history suggestive of
common bile duct lithiasis (80% vs. 68%), and personal or familial
history of primary liver cancer (6% vs. 1%). One (1.5%) out of 68
controls who had an expert ultrasound focused on signs of
intrahepaticmicrolithiasis showed typical features of LPAC syndrome.
In line with this, the frequency of LPAC syndrome within all patients
with symptomatic cholelithiasis varied from 0.5% to 1.9%.
Conclusion: Common bile duct stone in young patients with no prior
history of cholecystectomy should suggest LPAC syndrome. LPAC
patients with ABCB4 alteration seemmore exposed to the risk of ICP,
chronic cholestasis, and personal or familial primary liver cancer.
LPAC syndrome represents about 1% of patients with symptomatic
cholelithiasis.
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Background and Aims: Alpha-1 antitrypsin deficiency (A1AD) is an
autosomal codominant disease associated with an increased risk of
liver and lung disease in adults. The association between liver disease
and homozygosity for the mutant Z allele (PiZZ) is well-established,
however, the contribution of other genotypes to the pathogenesis of
adult liver disease is unclear. We aimed to assess the prevalence of
liver fibrosis in different A1AD genotypes, including rare variants.
Method: Multicenter cross-sectional case-control study, including
adult A1AD patients treated in pneumology departments of four
Portuguese academic and one non-academic centers. Data pertaining
pulmonary function and imaging were retrospectively collected.
Clinical, biochemical, and liver stiffness (LS) measured by transient
elastography (TE, Fibroscan) datawere prospectively collected at time
of enrollment. Significant liver fibrosis was defined by LS values
≥7.0 kPa. Patients with concomitant liver diseases were excluded.
Controls were recruited within a prospective epidemiological study
in the general adult population.
Results: 142 cases and 200 controls were included. Our study
comprised 47 PiZZ, as well as 76 PiZ heterozygotes (38 MZ, 34 SZ,
3 MheerlenZ, 1 ZQ0s), 10 PiS (5 SS, 5 MS), and 9 PiMmalton or
PiMpalermo carriers. Cases and controls did not differ in terms of age,
BMI, alcohol consumption, serum lipid levels, or CAP. Cases had
significantly higher serum levels of ALT, AST and GGT (p < 0.0001)
compared to controls. CAP values were higher in A1AD patients but
the difference did not attain statistical significance (p = 0.114).
LS was 5.2 ± 1.5 kPa in controls and 6.0 ± 4.1 kPa in A1AD (p = 0.046)
being highest in PiZZ (7.3 ± 5.3 kPa) and PiZ heterozygotes (5.7 ±
3.6 kPa). Liver fibrosis was detected in 20% (29/142) of patients. The
genotype-specific prevalence was: PiZZ 34%(16/47), PiZ- 16%(12/76),
while none of the PiS carriers had significant liver fibrosis. Among
patients with rare A1AD variants, one PiMmalton/PiMmalton had
significant liver fibrosis. Liver fibrosis was statistically significantly
associated with lower alpha-1 antitrypsin (p < 0.0001) and higher
total cholesterol (p = 0.024). Importantly, only 18% (26/142) of
patients with liver fibrosis had abnormal liver tests.
Figure 1: Liver fibrosis by alpha-1 antitrypsin deficiency genetic group.
Conclusion: Akin to PiZZ, PiZ heterozygoty is associated with liver
fibrosis development. Moreover, our results suggest that rare A1AD
variants may also promote liver fibrogenesis. Routine laboratory tests
are not predictive of significant liver fibrosis, highlighting the need
for non-invasive methods such as TE in patients with A1AD.
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